SubsidieMeestersRevolutionary silk-based bioink for 3D printing of ex vivo bone marrow models to advance drug development and personalized medicine
The SILKink project aims to develop a silk-based bioink for 3D printing bone marrow tissue models to enhance stem cell culture and advance drug development and personalized medicine.
Projectdetails
Aim
The SILKink project aims to develop a breakthrough biocompatible hydrogel, i.e., a bioink, to 3D print bone marrow tissue models that can be used for robust culture of human stem cells. The use of silk as the basis for novel bioinks (SILKink) helps to recreate tailored bone marrow-like microenvironments that will enable new applications in drug development and personalized medicine for bone marrow diseases. Here, we aim to optimize and validate SILKink, further define the business opportunity, and found an investment-ready spin-off company to commercialize SILKink.
Unmet Need
Bone marrow stem cells are fragile and require highly specific surroundings to survive and differentiate. Therefore, the presence of a soft tissue environment mimicking the human bone marrow is critical for reproducible culturing of these cells.
There is a large unmet need for reproducible solutions that mimic the soft tissue of the bone marrow to allow advancements in drug development and personalized medicine approaches for bone marrow diseases.
Solution
We will develop SILKink: a revolutionary bioink that is uniquely based on silk to closely mimic the 3D soft tissue environment of the bone marrow. SILKink will provide a matrix that supports all bone marrow cells including hematopoietic stem and progenitor cells and allows for 3D printing ex vivo bone marrow stem cell models in the shape or volume desired.
Consortium
The consortium consists of the following partners:
- University of Pavia (UNIPV) - Responsible for SILKink optimization, manufacturing, and validation.
- CELLINK - Involved in product optimization and responsible for product development.
- Catalyze-Group – Venture Building Team (CAT) - Will bring commercial expertise to develop an optimal market access strategy for SILKink and assist UNIPV with founding a spin-off company to commercialize SILKink and make it investment-ready.
The SILKink prototype was developed during the FET Open project SilkFUSION, and the partners co-own the background IP.
Financiële details & Tijdlijn
Financiële details
| Subsidiebedrag | € 2.494.687 |
| Totale projectbegroting | € 2.494.687 |
Tijdlijn
| Startdatum | 1-6-2023 |
| Einddatum | 31-5-2026 |
| Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- UNIVERSITA DEGLI STUDI DI PAVIApenvoerder
- CELLINK BIOPRINTING AB
- Catalyze B.V.
Land(en)
Geen landeninformatie beschikbaar
Vergelijkbare projecten binnen EIC Transition
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactorThe project aims to upscale ex vivo production of universal platelets using innovative technologies to meet rising demand and ensure compatibility for patients with transfusion reactions. | EIC Transition | € 1.798.152 | 2022 | Details |
Better Bioprinting by Light-sheet LithographyB-BRIGHTER aims to develop a novel high-speed bioprinting technology for creating complex engineered tissues, enhancing drug testing and therapeutic applications while fostering healthcare innovation. | EIC Transition | € 2.093.331 | 2022 | Details |
Prefabricated Mature Blood Vessels and Tools for Vascularized 3D Cell CultureThe Vasc-on-Demand project aims to develop three innovative products for easy generation of vascularized 3D tissues, enhancing research and drug testing while reducing reliance on animal trials. | EIC Transition | € 2.488.750 | 2024 | Details |
Closing the European gap towards a large scale ex vivo platelet production built upon a silk-based scaffold bioreactor
The project aims to upscale ex vivo production of universal platelets using innovative technologies to meet rising demand and ensure compatibility for patients with transfusion reactions.
Better Bioprinting by Light-sheet Lithography
B-BRIGHTER aims to develop a novel high-speed bioprinting technology for creating complex engineered tissues, enhancing drug testing and therapeutic applications while fostering healthcare innovation.
Prefabricated Mature Blood Vessels and Tools for Vascularized 3D Cell Culture
The Vasc-on-Demand project aims to develop three innovative products for easy generation of vascularized 3D tissues, enhancing research and drug testing while reducing reliance on animal trials.
Vergelijkbare projecten uit andere regelingen
| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Human based bioinks to engineer physiologically relevant tissuesHumanINK aims to validate human-based bioinks for 3D bioprinting, creating advanced cell culture environments to enhance drug development and reduce reliance on animal testing. | ERC Proof of... | € 150.000 | 2022 | Details |
Bioactive reinforcing bioink for hybrid bioprinting of implantable boneThe project aims to develop 'BioForceInk,' a bioactive bioink for hybrid 3D bioprinting of vascularized bone implants, enhancing mechanical strength and biological functionality for clinical applications. | ERC Proof of... | € 150.000 | 2024 | Details |
PRInted Symbiotic Materials as a dynamic platform for Living Tissues productionPRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications. | EIC Pathfinder | € 2.805.403 | 2022 | Details |
Universal 3D printer bioink for Type 1 diabetes cell therapyUniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment. | ERC Proof of... | € 150.000 | 2024 | Details |
A novel support material for 3D bioprinting and post-printing tissue growth: Print and GrowThe "Print and Grow" project aims to enhance 3D bioprinting stability and viability of tissue constructs through a novel microgel support, optimizing for diverse tissue types and in vivo applications. | ERC Proof of... | € 150.000 | 2022 | Details |
Human based bioinks to engineer physiologically relevant tissues
HumanINK aims to validate human-based bioinks for 3D bioprinting, creating advanced cell culture environments to enhance drug development and reduce reliance on animal testing.
Bioactive reinforcing bioink for hybrid bioprinting of implantable bone
The project aims to develop 'BioForceInk,' a bioactive bioink for hybrid 3D bioprinting of vascularized bone implants, enhancing mechanical strength and biological functionality for clinical applications.
PRInted Symbiotic Materials as a dynamic platform for Living Tissues production
PRISM-LT aims to develop a flexible bioprinting platform using hybrid living materials to enhance stem cell differentiation with engineered helper cells for biomedical and food applications.
Universal 3D printer bioink for Type 1 diabetes cell therapy
Uniink aims to develop a high-throughput 3D bioprinting method for producing consistent, insulin-secreting microspheres as a viable alternative to islet transplantation for Type 1 Diabetes treatment.
A novel support material for 3D bioprinting and post-printing tissue growth: Print and Grow
The "Print and Grow" project aims to enhance 3D bioprinting stability and viability of tissue constructs through a novel microgel support, optimizing for diverse tissue types and in vivo applications.